Has the amyloid cascade hypothesis for Alzheimer's disease been proved?

Current Alzheimer Research

Volumn 3, Issue 1, 2006, Pages 71-73

  Hardy, John ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CALCIUM; GAMMA SECRETASE; PRESENILIN 1; TAU PROTEIN;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CALCIUM HOMEOSTASIS; CHROMOSOME 21; CONFERENCE PAPER; DOWN SYNDROME; GENE LOCUS; GENE NUMBER; GENE OVEREXPRESSION; GENETIC RISK; LINKAGE ANALYSIS; MUTATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; NEUROFIBRILLARY TANGLES; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 33645829653     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506775697098     Document Type: Conference Paper

References (28)

1. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 286: 184-185 (1992).
2. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharm Sci 12: 383-388 (1991).
3. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 6(4): 487-98 (1991).
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 19: 297(5580): 353-6 (2002).
5. Younkin SG. Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann Neurol 37(3): 287-8 (1995).
6. Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 22: 259(5094): 514-6 (1993).
7. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 27: 264(5163): 1336-40, (1994).
8. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 17: 360(6405): 672-4 (1992).
9. Hardy JA. Framing b-amyloid. Nature Genet 1: 233-234, (1992).
10. Olson JM, Goddard KA, Dudek DM. The amyloid precursor protein locus and very-late-onset Alzheimer disease. Am J Hum Genet 69(4): 895-9 (2001)
11. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 43(3): 380-3 (1998).
12. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid b-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med 2: 864-870 (1996).
13. Sisodia SS, St George-Hyslop PH. γ-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3(4): 281-90 (2002).
14. Haass C, Steiner H. Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol 12(12): 556-62 (2002).
15. Stutzmann GE, Caccamo A, LaFerla FM, Parker I. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci 14: 24(2): 508-13 (2004).
16. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 5: 430: 631-9 (2004).
17. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nature Genet 25: 402-405 (2000).
18. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced Neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293: 1487-1491 (2001).
19. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 5: 43(3): 321-32 (2004)
20. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9(4): 448-52 (2003).
21. Ghiso J, Revesz T, Holton J, Rostagno A, Lashley T, Houlden H, et al. Chromosome 13 dementia syndromes as models of neurodegeneration. Amyloid 8(4): 277-84 (2001).
22. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 13: 261(5123): 921-3 (1993).
23. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 14: 97(6): 2892-7 (2000).
24. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, et al. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290: 2304-05 (2000).
25. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, et al. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 22: 290(5500): 2303-4 (2000).
26. Wavrant-De Vrieze F, Crook R, Holmans P, Kehoe P, Owen MJ, Williams J, et al. Genetic variability at the amyloid-beta precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. Neurosci Lett 269: 67-70 (1999).
27. Glenner GG. The proteins and genes of Alzheimer's disease. Biomed Pharmacother 42(9): 579-84 (1988).
28. Masters CL, Beyreuther KT. The pathology of the amyloid A4 precursor of Alzheimer's disease. Ann Med 21(2): 89-90 (1989).